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Abstract  
Oral route is the most preferred route for administration of drugs. Tablets are the most popular oral formulation available in 
the market and preferred by the patients and physician alike. In long-term therapy for the treatment of chronic disease 
conditions, conventional formulations are required to be administered multiple doses and therefore have several 
disadvantages. The primary benefit of a sustained release dosage form compared to a conventional dosage form, is the 
uniform drug plasma concentration and therefore uniform therapeutic effect. Matrix system are favored because of their 
simplicity, patient compliance etc, than traditional drug delivery which have many drawbacks like repeated administration, 
fluctuation in blood concentration level etc. Introduction of Matrix tablet as Sustained release has given a new break through 
for novel drug delivery system (NDDS) in the field of Pharmaceutical technology. Matrix systems are widely used for the 
purpose of sustained release. It is the release system which prolongs and controlls the release of drug that is dissolved or 
dispersed. In fact, a matrix is defined as a well-mixed composite of one or more drugs with gelling agent i.e. hydrophilic 
polymers. By the sustained release method therapeutically effective concentration can be achieved in the systemic circulation 
over an extended period of time, thus achieving better compliance of patients. Numerous sustained release oral dosage 
forms such as membrane controlled system, matrices with water soluble/insoluble polymers or waxes and osmotic systems 
have been developed, intense research has been recently focused on the designed of sustained release systems for poorly 
water soluble drugs. 
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INTRODUCTION 
 
     The term “sustained release” is known to have existed in the 
medical and pharmaceutical literature for many decades. It has been 
constantly used to describe a pharmaceutical dosage form 
formulated to retard the release of a therapeutic agent such that its 
appearance in the systemic circulation is delayed and/or prolonged 
and its plasma profile sustained in duration. The onset of its 
pharmacological action is often delayed and the duration of its 
therapeutic effect is sustained1. 
     The terms Sustained release, prolonged release, modified 
release, extended release or depot formulations are used to identify 
drug delivery systems that are designed to achieve or extend 
therapeutic effect by continuously releasing medication over an 
extended period of time after administration of a single dose. One of 
the least complicated approaches to the manufacture of sustained 
release dosage forms involves the direct compression of blend of 
drug, retardant material and additives to formulate a tablet in which 
the drug is embedded in a matrix of the retardant. Alternatively drug 
and retardant blend may be granulated prior to compression. The 
materials most widely used in preparing matrix systems include both 
hydrophilic and hydrophobic polymers. Commonly available 
hydrophilic polymers include Hydroxypropylmethylcellulose (HPMC), 
Hydroxypropylcellulose (HPC), Hydroxyethyl cellulose (HEC), 
Xanthan gum, Sodium alginate, Poly (ethylene oxide) and cross-
linked homopolymers and copolymers of Acrylic acid. It is usually 
supplied in micronized forms because small particle size is critical to 
the rapid formation of gelatinous layer on the tablet surface.2-4 
 
OBJECTIVES5  
 
     Recently, controlled release drug delivery has become the 
standards in the modern pharmaceutical design and intensive 
research has been undertaken in achieving much better drug product 
effectiveness, reliability and safety. Oral sustain release drug 
delivery medication will continue to account for the largest share of 
drug delivery systems. Hence in this work to formulate tablets in 
order to avoid the first pass metabolism and increase the 
bioavailability. Hence in this work an attempt was made to formulate 
sustain release system for in order to achieve even plasma 
concentration profile up to 24 hrs. Reason for the selection of -API as 
a model drug, 
 Being BCS class II drug it is low soluble in water and highly 
permeable. And it is necessary to sustain the drug release.  
 Bioavailability after oral administration is 20% Silent features to 
design formulation in sustain release tablets.  
 Less risk of dose dumping.  
 Less inter and intra subject variability.  
 High degree of dispersion in the digestive tract thus minimizing 
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the risk of high local drug concentrations.  
 Drug may reach the site of optimum absorption in a reproducible 
fashion so reproducible bioavailability.  
 Transport of drug is independent of gastric emptying.  
 
Drawbacks of Conventional Dosage Forms6 
1. Increased chances of missing the dose of a drug with short 
halflife for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to 
under medication or over medication. 
3. A typical peak-valley plasma concentration time profile is 
obtained which makes attainment of steady-state condition 
difficult. 
4. The fluctuations in drug levels may lead to precipitation of 
adverse effects especially of a drug with small Therapeutic 
Index (TI) whenever over medication occur. 
 
The following are the rationale of developing SR7-9 
 To extend the duration of action of the drug. 
 To reduce the frequency of dosing. 
 To minimize the fluctuations in plasma level. 
 Improved drug utilization. 
 Less adverse effects. 
 
Advantages of Sustained Release Matrix Tablet10,11  
 Easy to manufacture.  
 Versatile, effective and low cost.  
 Can be made to release high molecular weight compounds.  
 The sustained release formulations may maintain therapeutic 
concentrations over prolonged periods.  
 The use of sustain release formulations avoids the high blood 
concentration.  
 Sustain release formulations have the potential to improve the 
patient compliance.  
 Reduce the toxicity by slowing drug absorption.  
 Increase the stability by protecting the drug from hydrolysis or 
other derivative changes in gastrointestinal tract.  
 Minimize the local and systemic side effects.  
 Improvement in treatment efficacy.  
 Minimize drug accumulation with chronic dosing.  
 Usage of less total drug.  
 Improvement of the ability to provide special effects.  
Ex: Morning relief of arthritis through bed time dosing. 
 
Disadvantages of Sustained Release Matrix Tablet 
1. The remaining matrix must be removed after the drug has been 
released.  
2. High cost of preparation.  
3. The release rates are affected by various factors such as, food 
and the rate transit through the gut.  
4. The drug release rates vary with the square root of time. Release 
rate continuously diminishes due to an increase in diffusional 
resistance and/or a decrease in effective area at the diffusion 
front. However, a substantial sustained effect can be produced 
through the use of very slow release rates, which in many 
applications are indistinguishable from zero-order.  
 
Terminology12, 13 
 
    Modified release delivery systems may be divided conveniently 
in to four categories. 
A. Delayed release 
B. Sustained release 
1) Controlled release 
2) Extended release 
C. Site specific targeting 
 D. Receptor targeting 
 
Delayed Release 
 
     These systems are those that use repetitive, intermittent 
dosing of a drug from one or more immediate release units 
incorporated into a single dosage form. Examples of delayed release 
systems include repeat action tablets and capsules and enteric-
coated tablets where timed release is achieved by a barrier coating.  
 
Sustained release 
 
     During the last two decades there has been remarkable 
increase in interest in sustained release drug delivery system. This 
has been due to various factor viz. the prohibitive cost of developing 
new drug entities, expiration of existing international patents, 
discovery of new polymeric materials suitable for prolonging the drug 
release and improvement in the therapeutic efficiency and safety 
achieved by these delivery systems. Now-a-days the technology of 
sustained release is also being applied to veterinary products. These 
systems also provide a slow release of drug over an extended period 
of time and also can provide some control, whether this be of a 
temporal or spatial nature or both of drug release in the body or in 
other words, the system is successful at maintaining constant drug 
levels in the target tissue or cells. 
 
Controlled Release 
 
     These systems include any drug delivery system that 
achieves slow release of drug over an extended period of time 
 
Extended Release 
 
     Pharmaceutical dosage forms that release the drug slower 
than normal manner at predetermined rate & necessarily reduce the 
dosage frequency by two folds. 
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Site specific targeting 
 
     These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is adjacent to or in the 
diseased organ or tissue. 
 
Receptor targeting 
 
     These systems refer to targeting of a drug directly to a certain 
biological location. In this case the target is the particular receptor for 
a drug within an organ or tissue. Site specific targeting and receptor 
targeting systems satisfy the spatial aspect of drug delivery and are 
also considered to be sustained drug delivery systems. 
 
DESIGN AND FORMULATION OF ORAL SUATAINED RELEASE 
DRUG DELIVERY SYSTEM12-16 
 
     The oral route of administration is the most preferred route 
due to flexibility in dosage form, design and patient compliance. But 
here one has to take into consideration, the various pH that the 
dosage form would encounter during its transit, the gastrointestinal 
motility, the enzyme system and its influence on the drug and the 
dosage form. The majority of oral sustained release systems rely on 
dissolution, diffusion or a combination of both mechanisms, to 
generate slow release of drug to the gastrointestinal milieu. 
Theoretically and desirably a sustained release delivery device, 
should release the drug by a zero-order process which would result 
in a blood level time profile similar to that after intravenous constant 
rate infusion. 
 
Sustained (zero-order) drug release has been attempted to be 
achieved with various classes of sustained drug delivery 
system 
 
1. Diffusion sustained system. 
i) Reservoir type. 
ii) Matrix type 
2. Dissolution sustained system. 
i) Reservoir type. 
ii) Matrix type 
3. Methods using Ion-exchange. 
4. Methods using osmotic pressure. 
5. pH independent formulations. 
6. Altered density formulations. 
 
Diffusion Sustained System 
 
     Basically diffusion process shows the movement of drug 
molecules from a region of a higher concentration to one of lower 
concentration.  
     The flux of the drug J (in amount / area -time), across a 
membrane in the direction of decreasing concentration is given by 
Fick’s law. 
 
J= - D dc/dx 
 
Where; 
D = diffusion coefficient in area/ time 
dc/dx = change of concentration 'c' with distance 'x' 
     In common form, when a water insoluble membrane encloses 
a core of drug, it must diffuse through the membrane. The drug 
release rate dm/ dt is given by 
 
dm/ dt= ADKΔ C/L 
 
Where; 
A = Area; K = Partition coefficient of drug between the membrane 
and drug core. 
L= Diffusion path length (i.e. thickness of coat). 
Δc= Concentration difference across the membrane. 
 
Reservoir Type 
 
     In the system, a water insoluble polymeric material encases a 
core of drug  (Figure 1). Drug will partition into the membrane and 
exchange with the fluid surrounding the particle or tablet. Additional 
drug will enter the polymer, diffuse to the periphery and exchange 
with the surrounding media. 
 
 
 
Fig1. Schematic representation of diffusion sustained drug release: 
 reservoir system 
Matrix Type 
 
     A solid drug is dispersed in an insoluble matrix (Figure 2) and 
the rate of release of drug is dependent on the rate of drug diffusion 
and not on the rate of solid dissolution. 
     Higuchi has derived the appropriate equation for drug release 
for this system: 
 
Q = Dε/ T [2 A –εCs] Cst½ 
 
Where; 
Q = Weight in gms of drug released per unit area of surface at time t. 
D = Diffusion coefficient of drug in the release medium. 
ε = Porosity of the matrix. 
Cs = Solubility of drug in release medium. 
T= Tortuosity of the matrix. 
A = Concentration of drug in the tablet, as gm/ml. 
 
 
 
Fig 2. Schematic representation of diffusion sustained drug release: 
 matrix system 
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Dissolution Sustained Systems 
 
     A drug with a slow dissolution rate is inherently sustained and 
for those drugs with high water solubility, one can decrease 
dissolution through appropriate salt or derivative formation. These 
systems are most commonly employed in the production of enteric 
coated dosage forms. To protect the stomach from the effects of 
drugs such as aspirin, a coating that dissolves in natural or alkaline 
media is used. This inhibits release of drug from the device until it 
reaches the higher pH of the intestine. In most cases, enteric coated 
dosage forms are not truly sustaining in nature, but serve as a useful 
function in directing release of the drug to a special site. The same 
approach can be employed for compounds that are degraded by the 
harsh conditions found in the gastric region. 
 
Reservoir Type 
 
     Drug is coated with a given thickness coating, which is slowly 
dissolved in the contents of gastrointestinal tract. By alternating 
layers of drug with the rate controlling coats as shown in figure 1, a 
pulsed delivery can be achieved. If the outer layer is quickly 
releasing bolus dose of the drug, initial levels of the drug in the body 
can be quickly established with pulsed intervals. Although this is not 
a true sustained release system, the biological effects can be similar. 
An alternative method is to administer the drug as group of beads 
that have coating of different thickness. This is shown in figure. Since 
the beads have different coating thickness, their release occurs in a 
progressive manner. Those with the thinnest layers will provide the 
initial dose. The maintenance of drug levels at late times will be 
achieved from those with thicker coating. This is the principle of the 
spansule capsule. Cellulose nitrate phthalate was synthesized and 
used as an enteric coating agent for acetyl salicylic acid tablets. 
 
Matrix Type 
 
     The more common type of dissolution sustained dosage form 
(as shown in figure 2). It can be either a drug impregnated sphere or 
a drug impregnated tablet, which will be subjected to slow erosion. 
Two types of dissolution sustained pulsed delivery systems 
 Single bead type device with alternating drug and rate-controlling 
layer. 
 Beads containing drug with differing thickness of dissolving coats. 
Amongst sustained release formulations, hydrophilic matrix 
technology is the most widely used drug delivery system due 
to following advantages: 
 Provide desired release profiles for a wide therapeutic drug 
category, dose and solubility. 
 Simple and cost effective manufacturing using existing tableting 
unit operation equipment. 
 Robust formulation. 
 Broad regulatory and patient acceptance. 
 Ease of drug release modulation through level and choice of 
polymeric systems and function coatings. 
 
 
Methods Using Ion Exchange 
 
     It is based on the formation of drug resin complex formed 
when aionic solution is kept in contact with ionic resins. The drug 
from these complexes gets exchanged 
     In gastrointestinal tract and released with excess of Na+ and 
Cl- present in gastrointestinal tract. 
 
Anion Exchangers: Resin+ - Drug- + Cl- goes to Resin+- Cl-+ Drug- 
Cation Exchangers: Resin- Drug+ + Na+ goes to Resin- - Na+ + 
Drug+ 
 
     These systems generally utilize resin compounds of water 
insoluble cross linked polymer. They contain salt forming functional 
group in repeating positions on the polymer chain. The rate of drug 
diffusion out of the resin is sustained by the area of diffusion, 
diffusional path length and rigidity of the resin which is function of the 
amount of cross linking agent used to prepare resins. The release 
rate can be further sustained by coating the drug resin complex by 
micro encapsulation process. 
 
Methods Using Osmotic Pressure 
 
     A semi permeable membrane is placed around a tablet, 
particle or drug solution that allows transport of water into the tablet 
with eventual pumping of drug solution out of the tablet through a 
small delivery aperture in tablet coating. 
     Two types of osmotically sustained systems are 
 Type A contains an osmotic core with drug. 
 Type B contains the drug in flexible bag with osmotic core 
surrounding. 
 
pH– Independent Formulations 
 
     The gastrointestinal tract has some unusual features for the 
oral route of drug administration with relatively brief transit time 
through the gastrointestinal tract, which constraint the length of 
prolongation, further the chemical environment throughout the length 
of gastrointestinal tract is constraint on dosage form design. Since 
most drugs are either weak acids or weak bases, the release from 
sustained release formulations is pH dependent. However, buffers 
such as salts of amino acids, citric acid, phthalic acid phosphoric 
acid or tartaric acid can be added to the formulation, to help to 
maintain a constant pH thereby rendering pH independent drug 
release. A buffered sustained release formulation is prepared by 
mixing a basic or acidic drug with one or more buffering agent, 
granulating with appropriate pharmaceutical excipients and coating 
with gastrointestinal fluid permeable film forming polymer. When 
gastrointestinal fluid permeates through the membrane, the buffering 
agents adjust the fluid inside to suitable constant pH thereby 
rendering a constant rate of drug release e.g. propoxyphene in a 
buffered sustained release formulation, which significantly increase 
reproducibility. 
 
Altered Density Formulations 
 
     It is reasonable to expect that unless a delivery system 
remains in the vicinity of the absorption site until most, if not all of its 
drug content is released, it would have limited utility. To this end, 
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several approaches have been developed to prolong the residence 
time of drug delivery system in the gastrointestinal tract. 
 
High Density Approach 
 
     In this approach the density of the pellets must exceed that of 
normal stomach content and should therefore be at least 1-4 gm/cm3. 
 
Low Density Approach 
 
     Globular shells which have an apparent density lower than 
that of gastric fluid can be used as a carrier of drug for sustained 
release purpose. 
 
Classification of matrix tablets 
On the Basis of Retardant Material Used: Matrix tablets can be 
divided in to 5 types 17-19 
Hydrophobic Matrices (Plastic matrices) 
 
     In this method of obtaining sustained release from an oral 
dosage form, drug is mixed with an inert or hydrophobic polymer and 
then compressed in to a tablet. Sustained release is produced due to 
the fact that the dissolving drug has diffused through a network of 
channels that exist between compacted polymer particles. Examples 
of materials that have been used as inert or hydrophobic matrices 
include polyethylene, polyvinyl chloride, ethyl cellulose and acrylate 
polymers and their copolymers. The rate-controlling step in these 
formulations is liquid penetration into the matrix. The possible 
mechanism of release of drug in such type of tablets is diffusion. 
Such types of matrix tablets become inert in the presence of water 
and gastrointestinal fluid. 
 
Lipid Matrices 
 
     These matrices are prepared by the lipid waxes and related 
materials. Drug release from such matrices occurs through both pore 
diffusion and erosion. Release characteristics are therefore more 
sensitive to digestive fluid composition than to totally insoluble 
polymer matrix. Carnauba wax in combination with stearyl alcohol or 
stearic acid has been utilized for retardant base for many sustained 
release formulation. 
 
Hydrophilic Matrices 
 
     Hydrophilic polymer matrix systems are widely used in oral 
controlled drug delivery because of their flexibility to obtain a 
desirable drug release profile, cost effectiveness and broad 
regulatory acceptance. The formulation of the drugs in gelatinous 
capsules or more frequently in tablets, using hydrophilic polymers 
with high gelling capacities as base excipients is of particular interest 
in the field of controlled release. Infact a matrix is defined as well 
mixed composite of one or more drugs with a gelling agent 
(hydrophilic polymer). These systems are called swellable controlled 
release systems. 
 
Biodegradable Matrices 
 
     These consist of the polymers which comprised of monomers 
linked to one another through functional groups and have unstable 
linkage in the backbone. They are biologically degraded or eroded by 
enzymes generated by surrounding living cells or by non-enzymatic 
process in to oligomers and monomers that can be metabolized or 
excreted. Examples are natural polymers such as proteins and 
polysaccharides; modified natural polymers; synthetic polymers such 
as aliphatic poly (esters) and poly anhydrides. 
 
Mineral Matrices 
 
     These consist of polymers which are obtained from various 
species of seaweeds. Example is Alginic acid which is a hydrophilic 
carbohydrate obtained from species of brown seaweeds 
(Phaephyceae) by the use of dilute alkali. 
 
On the Basis of Porosity of Matrix20-23 
 
     Matrix system can also be classified according to their 
porosity and consequently.  
 
Macro porous Systems 
 
     In such systems the diffusion of drug occurs through pores of 
matrix, which are of size range 0.1 to 1 μm. This pore size is larger 
than diffusant molecule size. 
 
Micro porous System 
 
     Diffusion in this type of system occurs essentially through 
pores. For micro porous systems, pore size ranges between 50 – 
200 A°, which is slightly larger than diffusant molecules size. 
 
Non-porous System 
 
     Non-porous systems have no pores and the molecules diffuse 
through the network meshes. In this case, only the polymeric phase 
exists and no pore phase is present. 
 
POLYMERS USED IN MATRIX TABLET24  
Hydrogels  
 
     Polyhydroxyethylemethylacrylate  (PHEMA),  Cross-linked 
polyvinyl  alcohol  (PVA),  Cross-linked  polyvinyl  pyrrolidone 
(PVP), Polyethylene oxide (PEO), Polyacrylamide (PA).   
 
Soluble polymers  
 
     Polyethyleneglycol  (PEG),  polyvinyl  alcohol  (PVA), 
Polyvinylpyrrolidone  (PVP),  Hydroxypropyl  methyl  cellulose 
(HPMC).   
 
Biodegradable polymers  
 
     Polylactic acid (PLA), Polyglycolic acid (PGA), 
Polycaprolactone (PCL), Polyanhydrides, Polyorthoesters. 
 
Non-biodegradable polymers  
 
     Polyethylene  vinyl  acetate  (PVA), Polydimethylsiloxane  
(PDS), Polyether  urethane  (PEU),  Polyvinyl  chloride  
(PVC),  Cellulose acetate (CA), Ethyl cellulose (EC).   
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Mucoadhesive polymers  
 
     Polycarbophil, Sodium carboxymethyl cellulose, Polyacrylic 
acid, Tragacanth, Methyl cellulose, Pectin. 
 
Natural gums  
 
     Xanthan gum, Guar gum, Karaya gum, Locust bean gum. 
 
Basic principle of drug release 25 
 
     In solution, drug diffusion will occur from a region of high 
concentration to the region of low concentration. This concentration 
gradient is the driving force for the drug diffusion, out of a system. 
Water diffuses into the system in analogous manner. There is an 
abundance of water in the surrounding medium and system should 
allow water penetration. The inside of the system has low water 
content initially than the surrounding medium. 
 
Drug release from matrix 26 
 
     Drug in the outside layer exposed to the bathing solution is 
dissolved first and then diffuses out of the matrix. This process 
continues with the interface between the bathing solution and the 
solid drug moving toward the interior. It follows that for this system to 
be diffusion controlled, the rate of dissolution of drug particles within 
the matrix must be much faster than the diffusion rate of dissolved 
drug leaving the matrix. Derivation of the mathematical model to 
describe this system involves the following assumptions: 
a) A pseudo-steady state is maintained during drug release. 
b) The diameter of the drug particles is less than the average 
distance of drug diffusion through the matrix. 
c)  The bathing solution provides sink conditions at all times. 
 
     The release behaviour for the system can be mathematically 
described by the following equation: 
 
DM/Dh = Co. Dh - Cs/2                          …….. (1) 
 
Where; 
DM = Change in the amount of drug released per unit area 
Dh = Change in the thickness of the zone of matrix that has been 
depleted of drug 
Co = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix. 
Additionally, according to diffusion theory: 
 
DM = (Dm. Cs / h).Dt                           ……… (2) 
 
Where; 
Dm = Diffusion coefficient in the matrix. 
h = Thickness of the drug-depleted matrix 
Dt = Change in time 
 
By combining equation 1 and equation 2 and integrating: 
 
M = [Cs. Dm. (2Co−Cs). t] ½                     ……… (3) 
 
     When the amount of drug is in excess of the saturation 
concentration, then: 
 
M = [2Cs. Dm. Co. t] ½                         ……… (4) 
 
     Equation 3 and equation 4 relate the amount of drug release 
to the square-root of time. Therefore, if a system is predominantly 
diffusion controlled, then it is expected that a plot of the drug release 
vs. square root of time will result in a straight line. Drug release from 
a porous monolithic matrix involves the simultaneous penetration of 
surrounding liquid, dissolution of drug and leaching out of the drug 
through tortuous interstitial channels and pores. 
     The volume and length of the openings must be accounted for 
in the drug release from a porous or granular matrix: 
 
M = [Ds.Ca.p/T. (2Co – p.Ca) t] ½                 ……… (5) 
 
Where; 
p = Porosity of the matrix 
t = Tortuosity 
Ca = solubility of the drug in the release medium 
Ds = Diffusion coefficient in the release medium. 
T = Diffusion path length 
 
For pseudo steady state, the equation can be written as: 
 
M = [2D.Ca .Co (p/T) t] ½                        ………(6) 
 
     The total porosity of the matrix can be calculated with the 
following equation: 
 
p = pa + Ca/ ρ + Cex/ ρex                        ……..(7) 
 
Where; 
p = Porosity 
ρ = Drug density 
pa = Porosity due to air pockets in the matrix 
ρex = Density of the water soluble excipients 
Cex = Concentration of water soluble excipients 
 
For the purpose of data treatment, equation 7 can be reduced to: 
 
M = k. t ½                                   ………(8) 
 
Where; 
”k” is a constant, so that the amount of drug released versus the 
square root of time will be linear, if the release of drug from matrix is 
diffusion-controlled. 
     If this is the case, the release of drug from a homogeneous 
matrix system can be controlled by varying the following parameters: 
 Initial concentration of drug in the matrix 
 Porosity 
 Tortuosity 
 Polymer system forming the matrix 
 Solubility of the drug. 
 
 
 
  Nagendrakumar et al., 
 
42
Components of matrix tablets 25 
 
These include: 
 Active drug 
 Release controlling agent(s): matrix formers 
 Matrix Modifiers, such as channelling agents and wicking agents 
 Solubilizers and pH modifiers 
 Lubricants and flow aid 
 Supplementary coatings to extend lag time further reduce drug 
release etc. 
 Density modifiers (if required) 
 
Effect of release limiting factor on drug release 9,14 
 
     The mechanistic analysis of controlled release of drug reveals 
that partition coefficient; diffusivity; diffusional path thickness and 
other system parameters play various rate determining roles in the 
controlled release of drugs from either capsules, matrix or sandwich 
type drug delivery systems. 
 
Polymer hydration 
 
     It is important to study polymer hydration/swelling process for 
the maximum number of polymers and polymeric combinations. The 
more important step in polymer dissolution include 
absorption/adsorption of water in more accessible places, rupture of 
polymer-polymer linking with the simultaneous forming of water-
polymer linking, separation of polymeric chains, swelling and finally 
dispersion of polymeric chain in dissolution medium. 
 
Drug solubility 
 
     Molecular size and water solubility of drug are important 
determinants in the release of drug from swelling and erosion 
controlled polymeric matrices. For drugs with reasonable aqueous 
solubility, release of drugs occurs by dissolution in infiltrating medium 
and for drugs with poor solubility release occurs by both dissolution 
of drug and dissolution of drug particles through erosion of the matrix 
tablet. 
 
Solution solubility 
 
     In view of in vivo (biological) sink condition maintained 
actively by hem perfusion, it is logical that all the in vitro drug release 
studies should also be conducted under perfect sink condition. In this 
way a better simulation and correlation of in vitro drug release profile 
with in vivo drug administration can be achieved. It is necessary to 
maintain a sink condition so that the release of drug is controlled 
solely by the delivery system and is not affected or complicated by 
solubility factor. 
 
Polymer diffusivity 
 
     The diffusion of small molecules in polymer structure is 
energy activated process in which the diffusant molecules moves to 
a successive series of equilibrium position when a sufficient amount 
of energy of activation for diffusion has been acquired by the 
diffusant is dependent on length of polymer chain segment, cross 
linking and crystallanity of polymer. 
     The release of drug may be attributed to the three factors viz, 
I. Polymer particle size 
II. Polymer viscosity 
III. Polymer concentration 
 
Polymer particle size 
 
     Malamataris stated that when the content of hydroxyl propyl 
methylcellulose is higher, the effect of particle size is less important 
on the release rate of propanolol hydrochloride, the effect of this 
variable more important when the content of polymer is low. He also 
justified these results by considering that in certain areas of matrix 
containing low levels of hydroxyl propyl methylcellulose led to the 
burst release. 
 
Polymer viscosity 
 
     With cellulose ether polymers, viscosity is used as an 
indication of matrix weight. Increasing the molecular weight or 
viscosity of the polymer in the matrix formulation increases the gel 
layer viscosity and thus slows drug dissolution. Also, the greater 
viscosity of the gel, the more resistant the gel is to dilution and 
erosion, thus controlling the drug dissolution. 
 
Polymer concentration 
 
     An increase in polymer concentration causes an increase in 
the viscosity of gel as well as formulation of gel layer with a longer 
diffusional path. This could cause a decrease in the effective 
diffusion coefficient of the drug and therefore reduction in drug 
release. The mechanism of drug release from matrix also changes 
from erosion to diffusion as the polymer concentration increases. 
 
Thickness of polymer diffusional path 
 
     The controlled release of a drug from both capsule and matrix 
type polymeric drug delivery system is essentially governed by Fick’s 
law of diffusion: 
 
JD = D dc/dx 
 
Where;      
JD is flux of diffusion across a plane surface of unit area 
D is diffusibility of drug molecule, 
dc/dx is concentration gradient of drug molecule across a diffusion 
path with thickness dx. 
 
Thickness of hydrodynamic diffusion layer 
 
     It was observed that the drug release profile is a function of 
the variation in thickness of hydrodynamic diffusion layer on the 
surface of matrix type delivery devices. The magnitude of drug 
release value decreases on increasing the thickness of 
hydrodynamic diffusion layer. 
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Drug loading dose 
 
     The loading dose of drug has a significant effect on resulting 
release kinetics along with drug solubility. The effect of initial drug 
loading of the tablets on the resulting release kinetics is more 
complex in case of poorly water soluble drugs, with increasing initial 
drug loading the relative release rate first decreases and then 
increases, whereas, absolute release rate monotonically increases. 
In case of freely water soluble drugs, the porosity of matrix upon 
drug depletion increases with increasing initial drug loading. This 
effect leads to increased absolute drug transfer rate. But in case of 
poorly water soluble drugs another phenomenon also has to be 
taken in to account. When the amount of drug present at certain 
position within the matrix, exceeds the amount of drug soluble under 
given conditions, the excess of drug has to be considered as non-
dissolved and thus not available for diffusion. The solid drug remains 
within tablet, on increasing the initial drug loading of poorly water 
soluble drugs, the excess of drug remaining with in matrix increases. 
 
Surface area and volume 
 
     The dependence of the rate of drug release on the surface 
area of drug delivery device is well known theoretically and 
experimentally. Both the in vitro and in vivo rate of the drug release, 
are observed to be dependent upon surface area of dosage form. 
Siepman et al. found that release from small tablet is faster than 
large cylindrical tablets. 
 
Diluent’s effect 
 
     The effect of diluent or filler depends upon the nature of 
diluent. Water soluble diluents like lactose cause marked increase in 
drug release rate and release mechanism is also shifted towards 
fickian diffusion; while insoluble diluents like dicalcium phosphate 
reduce the fickian diffusion and increase the relaxation (erosion) rate 
of matrix. The reason behind this is that water soluble filler in 
matrices stimulate the water penetration in to inner part of matrix, 
due to increase in hydrophilicity of the system, causing rapid 
diffusion of drug, leads to increased drug release rate. 
 
Additives 
 
     The effect of adding non-polymeric excipients to a polymeric 
matrix has been claimed to produce increase in release rate of 
hydrosoluble active principles. These increases in release rate would 
be marked if the excipients are soluble like lactose and less 
important if the excipients are insoluble like tricalcium phosphate. 
 
Biological factors influencing release from matrix tablet8,14,27,28 
 Biological half-life. 
 Absorption. 
 Distribution. 
 Metabolism. 
 Protein binding. 
 Margin of safety. 
 
 
Biological Half-Life 
 
     The usual goal of an oral sustained-release product is to 
maintain therapeutic blood levels over an extended period. The 
elimination rate is quantitatively described by the half-life. Each drug 
has its own characteristic elimination rate, which is the sum of all 
elimination process, including metabolism, urinary excretion, and all 
other processes that permanently remove drug from the bloodstream. 
     Therapeutic compound with short half-lives are excellent 
candidates for sustained release preparations since, this can reduce 
dosing frequency. However, this is limited, in that drug with very 
short half-lives may require excessively large amounts of drug in 
each dosage unit to maintain sustained effect, forcing the dosage 
form itself to become limitingly large. In general, drugs with half-lives 
shorter than 2 hours are poor candidates for sustained-release 
preparations.  Compounds with long half-lives, more than 8 hours, 
are also generally not used in sustaining forms, since there effect is 
already sustained. 
 
Absorption 
 
     The characteristics of absorption of a drug can greatly affect 
its suitability as a sustained-release product. Since the purpose of 
forming a sustained-release product is to place control on the 
delivery system, it is necessary that the rate of release is much 
slower than the rate of absorption.  If we assume that the transits 
time of most drugs and devices in the absorptive areas of the GI tract 
is about 8-12 hours, the maximum half-life for absorption should be 
approximately 3-4 hours; otherwise, the device will pass out of the 
potential absorptive regions before drug release is complete. This 
corresponds to a minimum apparent absorption rate constant of 
0.17-0.23/ hrs  to give 80-95% over this time period. The absorption 
rate constant is an apparent rate constant and should in actuality, be 
the release rate constant of the drug from the dosage form. 
Compounds that demonstrate true lower absorption rate constants 
will probably be poor candidates for sustaining system. 
 
Distribution 
 
     The distribution of drugs into tissue can be an important factor 
in the overall drug elimination kinetics since it not only lowers the 
concentration of circulating drug but it also can be rate  limiting in its 
equilibration with blood and extracellular fluid. One aspect of this 
distribution is binding of drug to tissue and proteins in blood. The 
apparent volume of distribution of a drug is frequently used to 
describe the magnitude of distribution, including binding, within the 
body.  For design of sustained/controlled release products one 
would like to have as much information on drug disposition as 
possible but, in reality, decisions are usually based on only a few 
pharmacokinetic parameter, one of which is the apparent volume of 
distribution. 
 
Metabolism 
 
     Drugs that are significantly metabolized before absorption, 
either in the lumen or tissue of the intestine, can show decreased 
bioavailability from slower-releasing dosage forms. Most intestinal 
wall enzyme systems are saturable. As the drug is released at a 
slower rate to these regions, less total drug is presented to the 
enzymatic process during specific period, allowing more complete 
  Nagendrakumar et al., 
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conversion of the drug to its metabolites. Formulation of these 
enzymatically susceptible compounds as prodrugs is another viable 
solution. 
 
Protein Binding   
 
     The Pharmacological response of drug depends on unbound 
drug concentration drug rather than total concentration and all drug 
bound to some extent to plasma and or tissue proteins. Proteins 
binding of drug play a significant role in its therapeutic effect 
regardless the type of dosage form as extensive binding to plasma 
increase biological half-life and thus sometimes SR drug delivery 
system is not required for this type of drug. 
 
Margin of safety 
 
     As we know larger the value of therapeutic index safer is the 
drug. Drugs with less therapeutic index usually poor candidate for 
formulation of oral SR drug delivery system due to technological 
limitation of control over release rates. 
 
Physicochemical factors influencing release from matrix Tablet: 
13,28-30 
Dose size 
 
     For orally administered systems, there is an upper limit to the 
bulk size of the dose to be administered. In general, a single dose of 
0.5-1.0g is considered maximal for a conventional dosage form. This 
also holds for sustained release dosage form. Compounds that 
require large dosing size can sometimes be given in multiple 
amounts or formulated into liquid systems. Another consideration is 
the margin of safety involved in administration of large amount of a 
drug with a narrow therapeutic range. 
 
Ionization, pka and aqueous solubility 
 
     Most drugs are weak acids or bases. Since the unchanged 
form of a drug preferentially permeates across lipid membranes, it is 
important to note the relationship between the pka of the compound 
and the absorptive environment. Presenting the drug in an 
unchanged form is advantageous for drug permeation. Unfortunately, 
the situation is made more complex by the fact that the drug’s 
aqueous solubility will generally be decreased by conversion to 
unchanged form. Delivery systems that are dependent on diffusion or 
dissolution will  be dependent on the solubility of the drug in 
aqueous media. These dosage forms must function in an 
environment of changing pH, the stomach being acidic and the small 
intestine more neutral, the effect of phone the release process must 
be defined. Compounds with very low solubility (<0.01mg/ml) are 
inherently sustained, since their release over the time course of a 
dosage form in the GI tract will be limited by dissolution of the drug. 
So it is obvious that the solubility of the compound will be poor 
choices for slightly soluble drugs, since the driving force for diffusion, 
which is the drug’s concentration in solution, will be low. 
 
Partition Coefficient 
 
     When a drug is administered to the GI tract, it must cross a 
variety of biological membranes to produce a therapeutic effect in 
another area of the body. It is common to consider that these 
membranes are lipidic; therefore the partition coefficient of oil-soluble 
drugs becomes important in determining the effectiveness of 
membrane barrier penetration. Compounds which are lipophilic in 
nature having high partition coefficient are poorly aqueous soluble 
and they retain in the lipophilic tissue for the longer time. In case of 
compounds with very low partition coefficient, it is very difficult for 
them to penetrate the membrane, resulting in poor bioavailability. 
Furthermore, partitioning effects apply equally to diffusion through 
polymer membranes. The choice of diffusion-limiting membranes 
most largely depend on the partitioning characteristics of the drug. 
 
Stability 
 
     Orally administered drugs can be subjected to both acid-base 
hydrolysis and enzymatic degradation. Degradation will proceed at a 
reduced rate for drugs in solid state; therefore, this is the preferred 
composition of drug delivery for problem cases. For the dosage form 
that are unstable in stomach, systems that prolong delivery over 
entire course of transit in the GI tract are beneficial; this is also true 
for systems that delay release until the dosage form reaches the 
small intestine. Compounds that are unstable in small intestine may 
demonstrate decreased bioavailability when administered from a 
sustaining dosage form. This is because more drugs are delivered in 
the small intestine and hence, are subjected to degradation. 
Propentheline and probanthine are representative example of such 
drug. 
 
Evaluation Parameters for Extended Release Tablets31-34 
 
     To design a tablet and later monitor its quality, quantitative 
evaluation and assessment are done on the basis of its physical, 
chemical and pharmacokinetic properties. The tablets made are 
evaluated for the routine checks for the tablets such as average 
weight, thickness, hardness, weight variation etc. The main 
parameter required to be monitored while formulating an extended 
release tablets is in vitro release of the drug and that is in turn 
demonstrated by dissolution profile. 
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